Bladder cancer diagnostics company Pacific Edge has announced a $20 million capital raising alongside a half-year loss as its US market breakthrough remains elusive.
At balance date, Pacific Edge had cash and short-term deposits of $4.7m, a sum well below its operating cashflow in the six months
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
